{"disease": {"name": "Marginal zone lymphoma", "mondo_id": null, "ncit_id": null, "umls_id": null, "oncotree_code": "mixed"}, "updated_at": "2026-09-26", "genome_builds": ["hg19"], "cohort_count": 1, "cohort_count_status": "observed", "cohort_count_unit": "cohorts", "evaluable_patients": null, "evaluable_patients_status": "unknown", "evaluable_patients_unit": "patients", "alteration_types": ["SNV", "small indel", "amplification", "deep deletion"], "genes": [{"gene": "MYD88", "alteration_types": [], "altered": 0, "tested": 43, "frequency": 0.0, "cohort_count": 0, "frequency_range": {"min": 0.0, "max": 0.0}, "major_variants": [], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 0/43 patients (0.0%).", "Observed in 0 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 0, "tested": 43, "frequency": 0.0, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 0.0, "width": 1.0, "reference": 0.0, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 0, "tested": 43, "frequency": 0.0, "is_mutation": true}, "fda_badge": null, "altered_status": "not_observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "not_observed", "frequency_unit": "percent", "cohort_count_status": "not_observed", "cohort_count_unit": "cohorts"}, {"gene": "KLF2", "alteration_types": [], "altered": null, "tested": null, "frequency": null, "cohort_count": 0, "frequency_range": {"min": null, "max": null}, "major_variants": [], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Observed in 0 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": null, "headline_alteration": {"kind": "SNV / small indel", "altered": 0, "tested": null, "frequency": 0.0, "is_mutation": true}, "fda_badge": null, "altered_status": "not_assayed", "altered_unit": "patients", "tested_status": "not_assayed", "tested_unit": "patients", "frequency_status": "not_assayed", "frequency_unit": "percent", "cohort_count_status": "not_observed", "cohort_count_unit": "cohorts"}, {"gene": "NOTCH2", "alteration_types": ["SNV / small indel"], "altered": 6, "tested": 43, "frequency": 13.95, "cohort_count": 1, "frequency_range": {"min": 13.95, "max": 13.95}, "major_variants": ["L2301Cfs*9 (n=1)", "Q2285* (n=1)", "I2304Hfs*9 (n=1)", "I2304Mfs*2 (n=1)", "S2134* (n=1)"], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 6/43 patients (13.95%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 6, "tested": 43, "frequency": 13.95, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 46.5, "width": 1.0, "reference": 46.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 6, "tested": 43, "frequency": 13.95, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "TNFAIP3", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 13, "tested": 43, "frequency": 30.23, "cohort_count": 1, "frequency_range": {"min": 30.23, "max": 30.23}, "major_variants": ["L120Ffs*20 (n=2)", "Q503* (n=1)", "F395Lfs*4 (n=1)", "D134Rfs*6 (n=1)", "R271* (n=1)"], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 13/43 patients (30.23%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 13, "tested": 43, "frequency": 30.23, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 100.0, "width": 1.0, "reference": 100.0, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 13, "tested": 43, "frequency": 30.23, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "BIRC3", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["C557* (n=1)", "E518* (n=1)"], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "MALT1", "alteration_types": [], "altered": 0, "tested": 43, "frequency": 0.0, "cohort_count": 0, "frequency_range": {"min": 0.0, "max": 0.0}, "major_variants": [], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 0/43 patients (0.0%).", "Observed in 0 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 0, "tested": 43, "frequency": 0.0, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 0.0, "width": 1.0, "reference": 0.0, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 0, "tested": 43, "frequency": 0.0, "is_mutation": true}, "fda_badge": null, "altered_status": "not_observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "not_observed", "frequency_unit": "percent", "cohort_count_status": "not_observed", "cohort_count_unit": "cohorts"}, {"gene": "CARD11", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["M360V (n=1)", "D357E (n=1)"], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "KMT2D", "alteration_types": ["SNV / small indel"], "altered": 8, "tested": 43, "frequency": 18.6, "cohort_count": 1, "frequency_range": {"min": 18.6, "max": 18.6}, "major_variants": ["R5340* (n=2)", "Q3930* (n=1)", "R1252* (n=1)", "Q3974* (n=1)", "Q2033* (n=1)"], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 8/43 patients (18.6%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 8, "tested": 43, "frequency": 18.6, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 62.0, "width": 1.0, "reference": 62.0, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 8, "tested": 43, "frequency": 18.6, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "PTPRD", "alteration_types": [], "altered": null, "tested": null, "frequency": null, "cohort_count": 0, "frequency_range": {"min": null, "max": null}, "major_variants": [], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Observed in 0 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": null, "headline_alteration": {"kind": "SNV / small indel", "altered": 0, "tested": null, "frequency": 0.0, "is_mutation": true}, "fda_badge": null, "altered_status": "not_assayed", "altered_unit": "patients", "tested_status": "not_assayed", "tested_unit": "patients", "frequency_status": "not_assayed", "frequency_unit": "percent", "cohort_count_status": "not_observed", "cohort_count_unit": "cohorts"}, {"gene": "TP53", "alteration_types": ["SNV / small indel"], "altered": 3, "tested": 43, "frequency": 6.98, "cohort_count": 1, "frequency_range": {"min": 6.98, "max": 6.98}, "major_variants": ["R290Cfs*18 (n=1)", "T256K (n=1)", "C275Y (n=1)", "N263S (n=1)"], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 3/43 patients (6.98%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 3, "tested": 43, "frequency": 6.98, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 23.27, "width": 1.0, "reference": 23.27, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 3, "tested": 43, "frequency": 6.98, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "BTK", "alteration_types": [], "altered": 0, "tested": 43, "frequency": 0.0, "cohort_count": 0, "frequency_range": {"min": 0.0, "max": 0.0}, "major_variants": [], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 0/43 patients (0.0%).", "Observed in 0 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 0, "tested": 43, "frequency": 0.0, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 0.0, "width": 1.0, "reference": 0.0, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 0, "tested": 43, "frequency": 0.0, "is_mutation": true}, "fda_badge": null, "altered_status": "not_observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "not_observed", "frequency_unit": "percent", "cohort_count_status": "not_observed", "cohort_count_unit": "cohorts"}, {"gene": "MS4A1", "alteration_types": [], "altered": null, "tested": null, "frequency": null, "cohort_count": 0, "frequency_range": {"min": null, "max": null}, "major_variants": [], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Observed in 0 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": null, "headline_alteration": {"kind": "SNV / small indel", "altered": 0, "tested": null, "frequency": 0.0, "is_mutation": true}, "fda_badge": null, "altered_status": "not_assayed", "altered_unit": "patients", "tested_status": "not_assayed", "tested_unit": "patients", "frequency_status": "not_assayed", "frequency_unit": "percent", "cohort_count_status": "not_observed", "cohort_count_unit": "cohorts"}, {"gene": "TNFRSF14", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 5, "tested": 43, "frequency": 11.63, "cohort_count": 1, "frequency_range": {"min": 11.63, "max": 11.63}, "major_variants": ["W12* (n=2)", "Q182* (n=2)", "C96G (n=1)", "T18Pfs*4 (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 5/43 patients (11.63%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 5, "tested": 43, "frequency": 11.63, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 38.77, "width": 1.0, "reference": 38.77, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 5, "tested": 43, "frequency": 11.63, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "CCND3", "alteration_types": ["SNV / small indel"], "altered": 5, "tested": 43, "frequency": 11.63, "cohort_count": 1, "frequency_range": {"min": 11.63, "max": 11.63}, "major_variants": ["Q276* (n=2)", "P270Lfs*54 (n=1)", "D286G (n=1)", "P284S (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 5/43 patients (11.63%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 5, "tested": 43, "frequency": 11.63, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 38.77, "width": 1.0, "reference": 38.77, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 5, "tested": 43, "frequency": 11.63, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "BCL10", "alteration_types": ["SNV / small indel"], "altered": 5, "tested": 43, "frequency": 11.63, "cohort_count": 1, "frequency_range": {"min": 11.63, "max": 11.63}, "major_variants": ["E140* (n=2)", "D139Efs*2 (n=1)", "N137I (n=1)", "I46Nfs*4 (n=1)", "Y154* (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 5/43 patients (11.63%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 5, "tested": 43, "frequency": 11.63, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 38.77, "width": 1.0, "reference": 38.77, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 5, "tested": 43, "frequency": 11.63, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "IRF8", "alteration_types": ["SNV / small indel"], "altered": 4, "tested": 43, "frequency": 9.3, "cohort_count": 1, "frequency_range": {"min": 9.3, "max": 9.3}, "major_variants": ["E94K (n=1)", "Q46P (n=1)", "S416* (n=1)", "T80A (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 4/43 patients (9.3%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 4, "tested": 43, "frequency": 9.3, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 31.0, "width": 1.0, "reference": 31.0, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 4, "tested": 43, "frequency": 9.3, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "CREBBP", "alteration_types": ["SNV / small indel"], "altered": 4, "tested": 43, "frequency": 9.3, "cohort_count": 1, "frequency_range": {"min": 9.3, "max": 9.3}, "major_variants": ["R1446H (n=1)", "N1604Tfs*31 (n=1)", "R1169C (n=1)", "C1421Y (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 4/43 patients (9.3%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 4, "tested": 43, "frequency": 9.3, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 31.0, "width": 1.0, "reference": 31.0, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 4, "tested": 43, "frequency": 9.3, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ARID1A", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 4, "tested": 43, "frequency": 9.3, "cohort_count": 1, "frequency_range": {"min": 9.3, "max": 9.3}, "major_variants": ["L299Gfs*65 (n=1)", "K1094M (n=1)", "P1897Afs*4 (n=1)", "R1950W (n=1)", "Q802Sfs*15 (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 4/43 patients (9.3%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 4, "tested": 43, "frequency": 9.3, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 31.0, "width": 1.0, "reference": 31.0, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 4, "tested": 43, "frequency": 9.3, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "XPO1", "alteration_types": ["SNV / small indel", "amplification"], "altered": 3, "tested": 43, "frequency": 6.98, "cohort_count": 1, "frequency_range": {"min": 6.98, "max": 6.98}, "major_variants": ["E571K (n=2)", "K88R (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 3/43 patients (6.98%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 3, "tested": 43, "frequency": 6.98, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 23.27, "width": 1.0, "reference": 23.27, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 3, "tested": 43, "frequency": 6.98, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "MEF2B", "alteration_types": ["SNV / small indel"], "altered": 3, "tested": 43, "frequency": 6.98, "cohort_count": 1, "frequency_range": {"min": 6.98, "max": 6.98}, "major_variants": ["X257_splice (n=1)", "P325L (n=1)", "Q7_S9delinsH (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 3/43 patients (6.98%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 3, "tested": 43, "frequency": 6.98, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 23.27, "width": 1.0, "reference": 23.27, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 3, "tested": 43, "frequency": 6.98, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "EP300", "alteration_types": ["SNV / small indel"], "altered": 3, "tested": 43, "frequency": 6.98, "cohort_count": 1, "frequency_range": {"min": 6.98, "max": 6.98}, "major_variants": ["L415P (n=1)", "L1463P (n=1)", "Y1414S (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 3/43 patients (6.98%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 3, "tested": 43, "frequency": 6.98, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 23.27, "width": 1.0, "reference": 23.27, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 3, "tested": 43, "frequency": 6.98, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ARID5B", "alteration_types": ["SNV / small indel"], "altered": 3, "tested": 43, "frequency": 6.98, "cohort_count": 1, "frequency_range": {"min": 6.98, "max": 6.98}, "major_variants": ["A618Pfs*11 (n=1)", "L59V (n=1)", "Y500Rfs*29 (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 3/43 patients (6.98%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 3, "tested": 43, "frequency": 6.98, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 23.27, "width": 1.0, "reference": 23.27, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 3, "tested": 43, "frequency": 6.98, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ACTG1", "alteration_types": ["SNV / small indel"], "altered": 3, "tested": 43, "frequency": 6.98, "cohort_count": 1, "frequency_range": {"min": 6.98, "max": 6.98}, "major_variants": ["T203P (n=1)", "R62C (n=1)", "T249A (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 3/43 patients (6.98%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 3, "tested": 43, "frequency": 6.98, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 23.27, "width": 1.0, "reference": 23.27, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 3, "tested": 43, "frequency": 6.98, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "TBL1XR1", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["C334R (n=1)", "D369E (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "STAG2", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["X925_splice (n=1)", "D116E (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "RRAGC", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["W115L (n=1)", "G73D (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "PAX5", "alteration_types": ["SNV / small indel", "amplification"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["D2N (n=1)", "P8S (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "MTOR", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["E1766K (n=1)", "C1483Y (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "MPEG1", "alteration_types": ["SNV / small indel", "amplification"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["C534Y (n=1)", "N608K (n=1)", "Q604R (n=1)", "A145T (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "MED12", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["A560T (n=1)", "V417D (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ID3", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["E107Nfs*19 (n=1)", "A102P (n=1)", "E53* (n=1)", "L40_D43delinsPHEPLLL (n=1)", "Q81H (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "HLA-A", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["H27R (n=1)", "V52G (n=1)", "L17Q (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "H1-4", "alteration_types": ["SNV / small indel", "amplification"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["A178P (n=1)", "P181S (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "FAS", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["L294* (n=1)", "T241Kfs*4 (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "EPHA7", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["V662L (n=1)", "T156M (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "EP400", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["G1612D (n=1)", "R1235Sfs*4 (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "DTX1", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["Y72S (n=1)", "G16C (n=1)", "H80R (n=1)", "K53T (n=1)", "L69V (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "CD79B", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["Y197N (n=1)", "Y197C (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "BCR", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["E181D (n=1)", "E66K (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ATRX", "alteration_types": ["SNV / small indel"], "altered": 2, "tested": 43, "frequency": 4.65, "cohort_count": 1, "frequency_range": {"min": 4.65, "max": 4.65}, "major_variants": ["K487Q (n=1)", "T662A (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, marginal zone lymphoma subset (2022), 2/43 patients (4.65%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "altered": 2, "tested": 43, "frequency": 4.65, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "44/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.5, "width": 1.0, "reference": 15.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 2, "tested": 43, "frequency": 4.65, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}], "variants": [], "genomic_events": [{"event_type": "copy_number", "gene": "TNFAIP3", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "TNFAIP3 deep deletion", "genomic_coordinate": null, "observed": 3, "observed_status": "observed", "observed_unit": "patients", "tested": 43, "tested_status": "observed", "tested_unit": "patients", "frequency": 6.98, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["heme_msk_impact_2022"], "source_ids": ["heme_msk_impact_2022_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "TNFRSF14", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "TNFRSF14 deep deletion", "genomic_coordinate": null, "observed": 1, "observed_status": "observed", "observed_unit": "patients", "tested": 43, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.33, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["heme_msk_impact_2022"], "source_ids": ["heme_msk_impact_2022_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "ARID1A", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "ARID1A deep deletion", "genomic_coordinate": null, "observed": 1, "observed_status": "observed", "observed_unit": "patients", "tested": 43, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.33, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["heme_msk_impact_2022"], "source_ids": ["heme_msk_impact_2022_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "XPO1", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "amplification", "event_label": "XPO1 amplification", "genomic_coordinate": null, "observed": 1, "observed_status": "observed", "observed_unit": "patients", "tested": 43, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.33, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["heme_msk_impact_2022"], "source_ids": ["heme_msk_impact_2022_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "PAX5", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "amplification", "event_label": "PAX5 amplification", "genomic_coordinate": null, "observed": 1, "observed_status": "observed", "observed_unit": "patients", "tested": 43, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.33, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["heme_msk_impact_2022"], "source_ids": ["heme_msk_impact_2022_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "MPEG1", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "amplification", "event_label": "MPEG1 amplification", "genomic_coordinate": null, "observed": 1, "observed_status": "observed", "observed_unit": "patients", "tested": 43, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.33, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["heme_msk_impact_2022"], "source_ids": ["heme_msk_impact_2022_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "H1-4", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "amplification", "event_label": "H1-4 amplification", "genomic_coordinate": null, "observed": 1, "observed_status": "observed", "observed_unit": "patients", "tested": 43, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.33, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["heme_msk_impact_2022"], "source_ids": ["heme_msk_impact_2022_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "FAS", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "FAS deep deletion", "genomic_coordinate": null, "observed": 1, "observed_status": "observed", "observed_unit": "patients", "tested": 43, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.33, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["heme_msk_impact_2022"], "source_ids": ["heme_msk_impact_2022_cna"], "evidence_confidence": "moderate", "details": null}], "modality_summary": [{"modality": "SNV / small indel", "available_cohorts": 1, "total_cohorts": 1}, {"modality": "Copy number (discrete)", "available_cohorts": 1, "total_cohorts": 1}, {"modality": "Structural variant (present, not read)", "available_cohorts": 0, "total_cohorts": 1}], "chromosome_summary": [], "cohorts": [{"name": "MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source": "cBioPortal", "accession": "heme_msk_impact_2022", "patients": {"value": 43, "status": "observed", "unit": "patients"}, "samples": {"value": 44, "status": "observed", "unit": "samples"}, "disease_subtype": "MSK-IMPACT Heme Tumors (MSK, 2022)", "assay_type": "targeted panel", "sequencing_method": "IMPACT-HEME-400 (44)", "genome_build": "hg19", "alteration_types_available": ["SNV", "small indel", "amplification", "deep deletion"], "genes_assayed": "panel genes only; per-gene denominators", "primary_or_metastatic": null, "age_group": null, "retrieved_at": "2026-09-26", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "source_record_id": "heme_msk_impact_2022", "is_demo": false, "assay_coverage": {"patients_with_calls": 43, "patients_in_roster": 43, "frequencies_computed": true, "samples_sequenced": 44, "samples_in_study": 2383, "hypermutated_patients": 0, "median_mutations_per_sample": 3.0, "reason": null}}], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, marginal zone lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "limitations": ["A cBioPortal public-API snapshot retrieved 2026-09-26; the page does not refresh source data at request time.", "Counts are patients with at least one non-silent call in the study's sequenced sample list; silent, intronic and UTR calls are excluded.", "For targeted-panel cohorts each gene divides by the patients whose panel carried it; a gene absent from the panel is shown as not assayed, not as zero.", "Copy-number rows use discrete calls (2 = high-level amplification, −2 = deep deletion) against the cohort's copy-number sample list, which is a different roster from the sequenced one.", "Cohorts are not pooled. Cross-study patient overlap has not been checked and no disease-wide frequency is reported.", "Structural variants and fusions are not read in this snapshot even where the study carries a profile; germline variants, mutational signatures, TMB and MSI are not reported.", "The gene set is the briefing's curated targets plus the reference cohort's most frequently mutated genes; it is not genome-wide."], "answer_block": ["In MSK-IMPACT Heme, marginal zone lymphoma subset (2022) (43 sequenced patients, targeted panel), the most frequently altered of the 40 genes shown are TNFAIP3 30.23%, KMT2D 18.6%, NOTCH2 13.95%, TNFRSF14 11.63%, CCND3 11.63%. Each figure divides by the patients on whom that gene could be called.", "Of the briefing's 12 curated targets, 3 are altered in under 2% of this cohort (MYD88, MALT1, BTK): targets by expression, dependency or drug label, not by mutation. Frequency is not targetability, in either direction.", "1 cohorts are shown and none are pooled; overlap between them has not been checked and there is no disease-wide percentage."], "key_findings": [{"finding": "TNFAIP3 is mutated in 13 of 43 patients in MSK-IMPACT Heme, marginal zone lymphoma subset (2022).", "numerator": 13, "denominator": 43, "frequency": 30.23, "cohorts": 1, "evidence_confidence": "low", "source": "heme_msk_impact_2022", "retrieved_at": "2026-09-26"}, {"finding": "KMT2D is mutated in 8 of 43 patients in MSK-IMPACT Heme, marginal zone lymphoma subset (2022).", "numerator": 8, "denominator": 43, "frequency": 18.6, "cohorts": 1, "evidence_confidence": "low", "source": "heme_msk_impact_2022", "retrieved_at": "2026-09-26"}, {"finding": "NOTCH2 is mutated in 6 of 43 patients in MSK-IMPACT Heme, marginal zone lymphoma subset (2022).", "numerator": 6, "denominator": 43, "frequency": 13.95, "cohorts": 1, "evidence_confidence": "low", "source": "heme_msk_impact_2022", "retrieved_at": "2026-09-26"}], "research_gaps": [{"kind": "Structural variants", "text": "Read the structural-variant profiles the studies carry; fusions are the defining event in several of these diseases."}, {"kind": "Context", "text": "Stage, subtype, age and treatment line are not attached to any count; the cohorts differ on all four."}, {"kind": "Interpretation", "text": "Activating versus inactivating, actionable versus not, and evidence level are not inferred here; the briefing's target table carries the drug and trial facts."}], "observations": [], "data_status": "PUBLIC SOURCE SNAPSHOT", "is_demo": false, "reference_cohort": "heme_msk_impact_2022", "region_events": [], "matrix": [{"label": "MYD88", "kind": "SNV / small indel", "gene": "MYD88", "cells": [{"cohort": "heme_msk_impact_2022", "status": "not_observed", "frequency": 0.0, "altered": 0, "tested": 43, "note": null}]}, {"label": "KLF2", "kind": "SNV / small indel", "gene": "KLF2", "cells": [{"cohort": "heme_msk_impact_2022", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "NOTCH2", "kind": "SNV / small indel", "gene": "NOTCH2", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 13.95, "altered": 6, "tested": 43, "note": null}]}, {"label": "TNFAIP3", "kind": "SNV / small indel", "gene": "TNFAIP3", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 30.23, "altered": 13, "tested": 43, "note": null}]}, {"label": "TNFAIP3", "kind": "deep deletion", "gene": "TNFAIP3", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.98, "altered": 3, "tested": 43, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "BIRC3", "kind": "SNV / small indel", "gene": "BIRC3", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "MALT1", "kind": "SNV / small indel", "gene": "MALT1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "not_observed", "frequency": 0.0, "altered": 0, "tested": 43, "note": null}]}, {"label": "CARD11", "kind": "SNV / small indel", "gene": "CARD11", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "KMT2D", "kind": "SNV / small indel", "gene": "KMT2D", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 18.6, "altered": 8, "tested": 43, "note": null}]}, {"label": "PTPRD", "kind": "SNV / small indel", "gene": "PTPRD", "cells": [{"cohort": "heme_msk_impact_2022", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "TP53", "kind": "SNV / small indel", "gene": "TP53", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.98, "altered": 3, "tested": 43, "note": null}]}, {"label": "BTK", "kind": "SNV / small indel", "gene": "BTK", "cells": [{"cohort": "heme_msk_impact_2022", "status": "not_observed", "frequency": 0.0, "altered": 0, "tested": 43, "note": null}]}, {"label": "MS4A1", "kind": "SNV / small indel", "gene": "MS4A1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "TNFRSF14", "kind": "SNV / small indel", "gene": "TNFRSF14", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 11.63, "altered": 5, "tested": 43, "note": null}]}, {"label": "TNFRSF14", "kind": "deep deletion", "gene": "TNFRSF14", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 2.33, "altered": 1, "tested": 43, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "CCND3", "kind": "SNV / small indel", "gene": "CCND3", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 11.63, "altered": 5, "tested": 43, "note": null}]}, {"label": "BCL10", "kind": "SNV / small indel", "gene": "BCL10", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 11.63, "altered": 5, "tested": 43, "note": null}]}, {"label": "IRF8", "kind": "SNV / small indel", "gene": "IRF8", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 9.3, "altered": 4, "tested": 43, "note": null}]}, {"label": "CREBBP", "kind": "SNV / small indel", "gene": "CREBBP", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 9.3, "altered": 4, "tested": 43, "note": null}]}, {"label": "ARID1A", "kind": "SNV / small indel", "gene": "ARID1A", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 9.3, "altered": 4, "tested": 43, "note": null}]}, {"label": "ARID1A", "kind": "deep deletion", "gene": "ARID1A", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 2.33, "altered": 1, "tested": 43, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "XPO1", "kind": "SNV / small indel", "gene": "XPO1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.98, "altered": 3, "tested": 43, "note": null}]}, {"label": "XPO1", "kind": "amplification", "gene": "XPO1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 2.33, "altered": 1, "tested": 43, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "MEF2B", "kind": "SNV / small indel", "gene": "MEF2B", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.98, "altered": 3, "tested": 43, "note": null}]}, {"label": "EP300", "kind": "SNV / small indel", "gene": "EP300", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.98, "altered": 3, "tested": 43, "note": null}]}, {"label": "ARID5B", "kind": "SNV / small indel", "gene": "ARID5B", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.98, "altered": 3, "tested": 43, "note": null}]}, {"label": "ACTG1", "kind": "SNV / small indel", "gene": "ACTG1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.98, "altered": 3, "tested": 43, "note": null}]}, {"label": "TBL1XR1", "kind": "SNV / small indel", "gene": "TBL1XR1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "STAG2", "kind": "SNV / small indel", "gene": "STAG2", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "RRAGC", "kind": "SNV / small indel", "gene": "RRAGC", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "PAX5", "kind": "SNV / small indel", "gene": "PAX5", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "PAX5", "kind": "amplification", "gene": "PAX5", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 2.33, "altered": 1, "tested": 43, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "MTOR", "kind": "SNV / small indel", "gene": "MTOR", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "MPEG1", "kind": "SNV / small indel", "gene": "MPEG1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "MPEG1", "kind": "amplification", "gene": "MPEG1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 2.33, "altered": 1, "tested": 43, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "MED12", "kind": "SNV / small indel", "gene": "MED12", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "ID3", "kind": "SNV / small indel", "gene": "ID3", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "HLA-A", "kind": "SNV / small indel", "gene": "HLA-A", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "H1-4", "kind": "SNV / small indel", "gene": "H1-4", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "H1-4", "kind": "amplification", "gene": "H1-4", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 2.33, "altered": 1, "tested": 43, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "FAS", "kind": "SNV / small indel", "gene": "FAS", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "FAS", "kind": "deep deletion", "gene": "FAS", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 2.33, "altered": 1, "tested": 43, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "EPHA7", "kind": "SNV / small indel", "gene": "EPHA7", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "EP400", "kind": "SNV / small indel", "gene": "EP400", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "DTX1", "kind": "SNV / small indel", "gene": "DTX1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "CD79B", "kind": "SNV / small indel", "gene": "CD79B", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "BCR", "kind": "SNV / small indel", "gene": "BCR", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}, {"label": "ATRX", "kind": "SNV / small indel", "gene": "ATRX", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.65, "altered": 2, "tested": 43, "note": null}]}]}